Brief: TC BioPharm Announces Complete Response In Minimal Residual Disease Patient
11/06/2025 14:17
June 11 (Reuters) - TC Biopharm (Holdings) PLC T0Uy.F: TC BIOPHARM ANNOUNCES COMPLETE RESPONSE IN MINIMAL RESIDUAL DISEASE (MRD) PATIENT Source text: ID:nPn7wGM8Wa Further company coverage: [T0Uy.F] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on TC Biopharm (Holdings)
See all newsBrief: Cytomed Therapeutics Completes Acquisition Of T Cell Technology From Uk To Treat Cancers In China And India
Brief: TC BioPharm Announces Complete Response In Minimal Residual Disease Patient
Brief: TCBP Announces Non-Binding Letter Of Intent To Acquire Commercial Stage Ophthalmic Pharmaceutical Company
Brief: TC Biopharm's Data Show A Favorable Response In Patients With Relapse Or Refractory AML
Brief: TCBP Trading Continues Unabated On Nasdaq Stock Exchange